Navigation Links
ProFibrix Reports Phase II Results of Hemostasis Product Fibrocaps(TM) and Appoints New Chief Medical Officer
Date:3/11/2010

LEIDEN, The Netherlands and SEATTLE, Washington, March 11, 2010 /PRNewswire/ -- ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the conclusion of the first Phase II trial testing its unique new hemostat Fibrocaps(TM). Promising preliminary data from the European multicenter, open-label trial show compelling safety and efficacy (time to hemostasis) profiles for Fibrocaps, and good performance of the delivery device.

Robert J. Porte, MD, PhD, principal investigator of the Phase II trial, said: "Fibrocaps is a highly promising new hemostat that has unique characteristics and demonstrates optimal efficacy. We are fully committed to assist ProFibrix with the further development of this product and look forward to bringing this important innovation in hemostasis to the clinic."

ProFibrix recently also appointed Paul A. Frohna, MD, PhD, as Chief Medical Officer. Dr. Frohna has extensive preclinical, clinical and regulatory experience, as well as with designing and running clinical trials in the U.S., Canada and Europe. He has held senior management positions at companies such as Fibrogen Inc., CV Therapeutics, and Genentech. Dr. Frohna's educational background includes an undergraduate pharmacy degree with Honors from the '/>"/>

SOURCE ProFibrix B.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ProFibrix Raises US $11 Million (EUR 8 million) in Series B Financing
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... , July 3, 2015 /PRNewswire/ ... hakea verkossa osoitteessa  http://www.openinnovationinscience.at ... Innovation in Science" -jatkokoulutusohjelmaan 22.7.2015 ... Gesellschaftin (LBG) tekemän, kansainvälisiä tutkijoita ... terveystieteiden kaksi suurinta haastetta ovat ...
(Date:7/3/2015)... WIEN , July 3, 2015 /PRNewswire/ ... fram till 22 september 2015 på  http://www.openinnovationinscience.at ... Open Innovation in Science" som hålls i ... Enligt en färsk undersökning med internationella forskare ... Gesellschaft (LBG) är hälsovetenskapens två största utmaningar ...
(Date:7/3/2015)... July 3, 2015 ... september 2015 på  http://www.openinnovationinscience.at om efteruddannelsesprogrammet ... finder sted i Wien ... af internationale forskere og videnskabsmænd foretaget af ... største udfordringer for sundhedsvidenskaben manglen på incitamenter ...
(Date:7/2/2015)... 2015  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual ... of intellectual property, today announced a litigation update. ... Verizon Services Corp. et al. , Case No. 1:14-cv-00721-GBL-TCB, ... District of Virginia , the Court ... certain key claims in favor of the Defendants on ...
Breaking Biology Technology:Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3
... Conn., Dec. 8, 2011  Cenestra Health announces that the ... a new U.S. patent, No. 8,071,646 (the ",646 patent"), ... pure formulations of eicosapentaenoic acid (EPA) and docosahexaenoic acid ... 5:1.  The ,646 patent provides exclusivity for these EPA:DHA ...
... 2011 /PRNewswire-iReach/ -- Z-Distribution is proud to ... best and most powerful weapons to fight and help ... is a natural process, no-one likes to see its ... are on display most of the time. ...
... Dec. 7, 2011 Generex Biotechnology Corporation ( www.generex.com ) ... by Professor Paolo Pozzilli at the University Campus Bio-Medico in ... using Generex Oral-lyn™  as it pertains to prediabetes at ... held in Dubai, December 3 rd -8 th , ...
Cached Biology Technology:Cenestra Health Announces Granting of Broad Patent Covering Proprietary Bioactive Lipid Formulations 2Cenestra Health Announces Granting of Broad Patent Covering Proprietary Bioactive Lipid Formulations 3Fytofontana Cosmeceuticals: The Swiss Secret For Incredibly Young And Beautiful Skin 2Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai 2Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai 3Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai 4
(Date:6/12/2015)... , June 12, 2015  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... its patent to electronically capture, analyze and identify ... facial recognition methods. This system can: ... by an enrollment and subsequent sign-on process is ...
(Date:6/10/2015)... 2015 According to a ... Technology (Ultrasound, TOF, Structured Light, Stereo Vision), Type(Image, ... and by Geography - Trends & Forecast to ... is expected to reach $3,319.71 Million by 2020, ... and 2020. Browse 71 market data ...
(Date:6/9/2015)... June 09, 2015 Research and Markets ... the "Gesture Recognition & Touchless Sensing Market ... Automotive, & Others), Product (Biometric & Sanitary Equipment) ... report to their offering. The ... expected to reach $ 23.55 Billion by 2020 ...
Breaking Biology News(10 mins):Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 23D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... www.ucr.edu ) -- Ever wonder how much fuel you ... not using air conditioning or coasting toward stops? ... Engineering Center for Environmental Research and Technology (CE-CERT) can ... called eco-driving, which refers to providing drivers with advice ...
... genetically modified crop may have been overemphasized, as modest rises ... farm management, says a new study by a Washington University ... PhD, professor of anthropology in Arts & Sciences, appears in ... In his paper, Stone compares village yields in 2003 ...
... Two Boston University School of Medicine (BUSM) faculty ... pharmacology and psychiatry and Michael Silverstein, MD, an ... prestigious National Institute of Mental Health (NIMH) Biobehavioral ... with ten other investigators from around the country. ...
Cached Biology News:Research helps drivers cut fuel use 2Research helps drivers cut fuel use 3New findings in India's Bt cotton controversy: Good for the field, bad for the farm? 2Boston University School of Medicine researchers receive NIMH brain awards 2
streptavidin, Alexa Fluor® 750–allophycocyanin conjugate (Alexa Fluor® 750–allophycocyanin streptavidin) *1 mg/mL*...
Biotin-OSu is used to label proteins, immunological agents, DNA and synthetic oligonucleotides. Biotin labeling is detected through enzymatically labeled avidin or streptavidin proteins that conforma...
RAT ANTI MOUSE JAM-2 Immunogen: Recombinant soluble JAM-2...
...
Biology Products: